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To the Editor: In the United 
States, almost 80% of tuberculosis 
(TB) cases are diagnosed on the 
basis of positive culture results for 
Mycobacterium tuberculosis, and 
>90% of initial isolates are tested 
for drug susceptibilities (1,2). 
Recommended treatment durations are 
6–9 months for patients with isoniazid- 
and rifampin-susceptible TB; <18 
months for patients with rifampin-
monoresistant TB; and, following 
culture conversion, 18–24 months for 
patients with isoniazid- and rifampin-
resistant TB (3). Appropriately 
completed TB treatment maximizes 
patient and public health beneﬁ  ts and 
minimizes adverse events and costs 
(3). We examined treatment duration 
by drug resistance pattern among a 
national cohort of case-patients with 
TB diagnosed in the United States.
We analyzed routinely collected 
data from the Centers for Disease 
Control and Prevention’s National 
TB Surveillance System. To ensure 
that all patients had at least 3 years 
of follow-up, we examined cases of 
culture-positive TB veriﬁ  ed in 2006. 
We calculated treatment duration 
for patients who were alive and had 
initiated TB therapy at diagnosis 
and who had results for initial drug 
susceptibility testing. Treatment 
duration was calculated by subtracting 
the therapy start date from the therapy 
end date. The 15th day of the month 
was assigned as the day treatment 
started or ended if that information was 
missing. Patients who did not complete 
therapy were censored as of the last 
known follow-up. We categorized 
cases as isoniazid monoresistant; 
rifampin monoresistant; multidrug 
resistant (MDR), deﬁ  ned as resistant 
to at least isoniazid and rifampin; 
or drug susceptible, deﬁ  ned  as 
susceptible to isoniazid, rifampin, 
and ethambutol and with no known 
resistance to pyrazinamide (i.e., 
pyrazinamide susceptible or missing 
test results). Survival distributions by 
drug-resistance pattern were estimated 
by using Kaplan-Meier analysis and 
compared by using log-rank test 
statistics. Patient characteristics were 
compared by using χ2 tests or, when 
cell sizes were <5, Fisher exact tests.
Of 13,734 TB cases reported 
in 2006, 10,747 (78.3%) were 
conﬁ  rmed by culture. Of the 10,747 
patients with culture-conﬁ  rmed  TB, 
10,120 (94.2%) were alive and had 
initiated TB therapy at diagnosis and 
had start and end therapy dates and 
initial drug susceptibility results. 
Duration of treatment was calculated 
for 9,734 (96.2%) cases, of which, 
8,973 (92.2%) were classiﬁ  ed  as 
drug-susceptible, 618 (6.3%) as 
isoniazid-monoresistant, 24 (0.2%) 
as rifampin-monoresistant, and 119 
(1.2%) as MDR TB. The remaining 
386 (3.8%) cases were excluded 
from analysis because the patients 
had pyrazinamide-monoresistant TB, 
suggestive of Mycobacterium bovis 
infection (165), or they were missing 
susceptibility testing results for 
isoniazid, rifampin, or ethambutol 
(112) or had other resistance patterns 
(109).
At 12 months, the cumulative 
completion of therapy among 
patients with drug-susceptible, 
isoniazid-monoresistant, rifampin-
monoresistant, or MDR TB was 
87.6%, 81.0%, 17.4%, and 1.9%, 
respectively (Figure). At 24 months, 
73.9% of patients with rifampin-
monoresistant TB and 40.2% with 
MDR TB had completed treatment. 
Treatment duration was shortest for 
patients with drug-susceptible TB 
(median 252 days), compared with a 
median of 274, 555, and 766 days for 
patients with isoniazid-monoresistant, 
rifampin-monoresistant, and MDR 
TB, respectively. Differences in 
treatment duration based on drug 
susceptibility were signiﬁ  cant 
(p<0.001) for all comparisons. The 
MDR TB group included 4 extensively 
drug-resistant cases (also resistant 
to any ﬂ   uoroquinolone and >1 of 
the injectable drugs capreomycin, 
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Figure. Treatment duration, by drug-resistance pattern, among reported tuberculosis case-
patients who completed treatment, United States, 2006. Cases were among patients who 
were alive and initiated therapy at diagnosis and who had start and end therapy dates as 
well as results for initial drug susceptibility testing to isoniazid, rifampin, and ethambutol. 
Susceptibility testing was conducted on culture-positive Mycobacterium tuberculosis 
isolates from any specimen type. A color version of this ﬁ  gure is available online (wwwnc.
cdc.gov/EID/article/18/7/12-0261-F.htm).LETTERS
kanamycin, or amikacin) (4); no 
remarkable change in duration of 
treatment resulted when those 4 cases 
were removed from analysis. 
The surveillance system captures 
only the initial treatment regimen; 
thus, we could not assess changes 
to treatment regimens in response 
to drug susceptibility test results or 
treatment nonadherence. We observed 
no difference in history of prior TB; 
HIV infection; or miliary, meningeal, 
pediatric, or bone and joint TB among 
case-patients with isoniazid-resistant 
versus drug-susceptible TB (p>0.12 
for all comparisons). TB treatment 
recommendations in the United 
States emphasize completion within 
12 months of initiating therapy, with 
exceptions for rifampin-resistant TB, 
meningeal TB, and disseminated 
disease in pediatric patients (children 
<15 years of age) (1,5). We found no 
change in treatment duration by drug-
resistance pattern after removing cases 
of meningeal TB or cases in children 
from analysis.
The length of TB treatment 
duration in the United States has 
improved since therapy outcomes 
were ﬁ  rst recorded in the National TB 
Surveillance System in 1993. In our 
study, 90% of case-patients with drug-
susceptible TB completed therapy 
within 373 days, compared with 671 
days in 1993 (6), and 90% of patients 
with isoniazid-monoresistant TB 
completed therapy within 432 days. 
Although the percentage of MDR TB 
cases in the United States has declined 
since 1993, drug resistance remains a 
serious concern because the percentage 
of isoniazid-monoresistant TB cases 
has remained stable (7). Our analysis 
suggests that despite the effectiveness 
of rifampin-containing regimens and 
an apparent lack of clinical differences 
to justify extending therapy, longer 
treatment durations persist among 
patients with isoniazid-monoresistant 
TB (8). In our cohort study, <75% of 
patients with rifampin-monoresistant 
TB and 40% with MDR TB completed 
therapy within 24 months, suggesting 
no improvement since 1993 in the 
length of treatment duration for 
rifampin-resistant TB strains (6).
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Exposure of US 
Travelers to Rabid 
Zebra, Kenya, 2011
To the Editor: Rabies is an acute 
progressive encephalitis caused by 
infection with a lyssavirus (genus 
Lyssavirus, family Rhabdoviridae) 
(1). Most human infections are caused 
by bites from rabid animals, but 
the virus also can be transmitted by 
contact of open wounds or mucous 
membranes with animal saliva (1,2). 
Prompt administration of postexposure 
prophylaxis (PEP) is recommended to 
prevent rabies (3). Canids are common 
sources of human exposures in many 
regions of Africa, Asia, and Latin 
America (4). However, all mammals 
are susceptible, including herbivores 
such as horses, cattle, and antelope 
(5–7).
Approximately 16–200 rabies 
virus exposures occur per 100,000 
international travelers (2). Travelers 
might be unaware of exposure risks 
from less commonly affected species 
because prevention guidelines focus 
on avoiding contact with feral and 
wild carnivores (primarily dogs) and 
bats (2). After travelers at a safari 
lodge in Kenya were exposed to a 
rabid zebra, the Centers for Disease 
Control and Prevention (CDC) and 
international partners conducted 
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